Ron Leuty

Two recently minted public companies signed large East Bay biotech leases recently, but Bay Area life sciences vacancy rates continued to climb and lease rates dropped in the first half.

A team that closed a potential $5.2 billion deal just seven months ago is dealing again.

One company went public in April. Now its spinout plans an IPO.

This 2-year-old San Francisco company filed plans for an IPO.

How startups, UCSF, top-tier VCs hope to build AI for healthcare

Can a nonprofit and small test maker change the face of Lyme disease?

California is back in court around 23andMe's 2023 data breach. Here's why the incident keeps coming up.

UC Berkeley and a Nobel Prize winner could score millions through this biotech company's planned IPO.

Meet the Bay Area's latest company to go public.

The Brisbane biotech company underwent five restructurings and faced a nearly $100 million patent judgment before its new CEO implemented a strategy that led to profitability and a major acquisition in the cancer testing space.